These cancer cells are expected to exhibit a vulnerability while they handle high levels of DNA replication stress, and exacerbating this replication stress using ATR inhibitors, or other checkpoint inhibitors that target CHK1 or WEE1, is thought to be a promising strategy for cancer therapy [139]. This evidence concerns the gene CHEK1 and cancer.